title: Pharmacological characterization of a new 4-amidinophenyl-alanine thrombin-inhibitor (CRC 220).
abstract: The new thrombin inhibitor CRC 220 was characterized in vivo for its antithrombotic effects. CRC 220 led to a dose-dependent prolongation of clotting parameters as determined in rats, rabbits, dogs, sheeps, pigs and monkeys. We evaluated the efficacy of CRC 220 to prevent thrombus formation in arteries and in the microcirculation in different animal models. In a rabbit model of tissue factor-induced coagulation activation, infusion of 0.5 mg/kg x h CRC 220 (3 hours) led to a significant prevention of fibrinogen decrease. In a rat model of lethal LPS-induced DIC CRC 220 significantly prevented the mortality rate after a 4h-infusion of 0.75 mg/kg x h. Thrombin-induced platelet aggregation in rat lungs could be prevented by the i.v. bolus injection of CRC 220. A dose of 0.3 mg/kg leads to a reduction of more than 80% of platelet deposition in the lung, significant inhibition was still observed 90 minutes after CRC 220 administration; at this time the inhibitor had already been cleared from plasma. Arterial thrombosis was induced in rabbits by squeezing and stenosis of the A. carotis. The i.v. bolus administration of CRC 220 dose-dependently prevented thrombus formation, an ED50 of 0.03 mg/kg was calculated. This dose was associated with only a minor prolongation of aPTT.
authors.affiliation: Research Laboratories of Behringwerke AG, Marburg, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Dickneite
authors.forename: D
authors.initials: D
authors.lastname: Seiffge
authors.forename: K H
authors.initials: KH
authors.lastname: Diehl
authors.forename: M
authors.initials: M
authors.lastname: Reers
authors.forename: J
authors.initials: J
authors.lastname: Czech
authors.forename: E
authors.initials: E
authors.lastname: Weinmann
authors.forename: D
authors.initials: D
authors.lastname: Hoffmann
authors.forename: W
authors.initials: W
authors.lastname: Stüber
mesh_terms: D000818:Animals; D000991:Antithrombins / Q000627:therapeutic use* / Q000633:toxicity; D001777:Blood Coagulation / Q000187:drug effects; D004151:Dipeptides / Q000627:therapeutic use* / Q000633:toxicity; D004211:Disseminated Intravascular Coagulation / Q000517:prevention & control; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D008252:Macaca fascicularis; D008297:Male; D051379:Mice; D010880:Piperidines / Q000627:therapeutic use* / Q000633:toxicity; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D012756:Sheep; D013552:Swine; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D000991:Antithrombins; C093375:CRC 220; D004151:Dipeptides; D010880:Piperidines; D010975:Platelet Aggregation Inhibitors